Hannes Kahlow1, Magnus Olivecrona. 1. Department of Pharmacology and Clinical Neuroscience, Umeå University, Section of Neurosurgery, Umeå University Hospital, Umeå, Sweden. Electronic address: hanneskahlow@hotmail.com.
Abstract
PURPOSE: To longitudinally study surgical and hardware complications to vagal nerve stimulation (VNS) treatment in patients with drug-resistant epilepsy. METHODS: In a longitudinal retrospective study, we analyzed surgical and hardware complications in 143 patients (81 men and 62 women) who between 1994 and 2010 underwent implantation of a VNS-device for drug-resistant epilepsy. The mean follow-up time was 62 ± 46 months and the total number of patient years 738. RESULTS: 251 procedures were performed on 143 patients. 16.8% of the patients were afflicted by complications related to surgery and 16.8% suffered from hardware malfunctions. Surgical complications were: superficial infection in 3.5%, deep infection needing explantation in 3.5%, vocal cord palsy in 5.6%, which persisted in at least 0.7% for over one year, and other complications in 5.6%. Hardware-related complications were: lead fracture in 11.9% of patients, disconnection in 2.8%, spontaneous turn-off in 1.4% and stimulator malfunction in 1.4%. We noted a tendency to different survival times between the two most commonly used lead models as well as a tendency to increased infection rate with increasing number of stimulator replacements. CONCLUSION: In this series we report on surgical and hardware complications from our 16 years of experience with VNS treatment. Infection following insertion of the VNS device and vocal cord palsy due to damage to the vagus nerve are the most serious complications related to the surgery. Avoiding unnecessary reoperations in order to reduce the appearances of these complications are of great importance. It is therefore essential to minimize technical malfunctions that will lead to additional surgery. Further studies are needed to evaluate the possible superiority of the modified leads. Crown
PURPOSE: To longitudinally study surgical and hardware complications to vagal nerve stimulation (VNS) treatment in patients with drug-resistant epilepsy. METHODS: In a longitudinal retrospective study, we analyzed surgical and hardware complications in 143 patients (81 men and 62 women) who between 1994 and 2010 underwent implantation of a VNS-device for drug-resistant epilepsy. The mean follow-up time was 62 ± 46 months and the total number of patient years 738. RESULTS: 251 procedures were performed on 143 patients. 16.8% of the patients were afflicted by complications related to surgery and 16.8% suffered from hardware malfunctions. Surgical complications were: superficial infection in 3.5%, deep infection needing explantation in 3.5%, vocal cord palsy in 5.6%, which persisted in at least 0.7% for over one year, and other complications in 5.6%. Hardware-related complications were: lead fracture in 11.9% of patients, disconnection in 2.8%, spontaneous turn-off in 1.4% and stimulator malfunction in 1.4%. We noted a tendency to different survival times between the two most commonly used lead models as well as a tendency to increased infection rate with increasing number of stimulator replacements. CONCLUSION: In this series we report on surgical and hardware complications from our 16 years of experience with VNS treatment. Infection following insertion of the VNS device and vocal cord palsy due to damage to the vagus nerve are the most serious complications related to the surgery. Avoiding unnecessary reoperations in order to reduce the appearances of these complications are of great importance. It is therefore essential to minimize technical malfunctions that will lead to additional surgery. Further studies are needed to evaluate the possible superiority of the modified leads. Crown
Authors: Peter B Weber; Ritu Kapur; Ryder P Gwinn; Richard S Zimmerman; Tracy A Courtney; Martha J Morrell Journal: Stereotact Funct Neurosurg Date: 2017-09-15 Impact factor: 1.875
Authors: Jesse Dawson; Charles Y Liu; Gerard E Francisco; Steven C Cramer; Steven L Wolf; Anand Dixit; Jen Alexander; Rushna Ali; Benjamin L Brown; Wuwei Feng; Louis DeMark; Leigh R Hochberg; Steven A Kautz; Arshad Majid; Michael W O'Dell; David Pierce; Cecília N Prudente; Jessica Redgrave; Duncan L Turner; Navzer D Engineer; Teresa J Kimberley Journal: Lancet Date: 2021-04-24 Impact factor: 79.321
Authors: Niels Hammer; Juliane Glätzner; Christine Feja; Christian Kühne; Jürgen Meixensberger; Uwe Planitzer; Stefan Schleifenbaum; Bernhard N Tillmann; Dirk Winkler Journal: PLoS One Date: 2015-02-13 Impact factor: 3.240
Authors: Ahmad Tamimi; Faleh Tamimi; Malik Juweid; Abdelkarim A Al-Qudah; Amira Al Masri; Said Dahbour; Yakub Al Bahou; Abdelatif Shareef; Iskandar Tamimi Journal: J Musculoskelet Neuronal Interact Date: 2021-06-01 Impact factor: 2.041